Document:

Amendment to Research, Development and License Agreement

 EXHIBIT 10.42 
  
 Portions of this exhibit were omitted and filed separately with the Secretary of the Commission pursuant to an application for confidential treatment filed with the
Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934. Such portions are marked by a series of asterisks. 
  
 December 18, 2003 
  
 BY FAX and FEDERAL EXPRESS 
  
 Novo Nordisk A/S 
 Novo Allé 
 2880 Bagsvaerd 
 Denmark 
  
     Attention: Vice President, Business Development 
     Fax: 011-45-4442-1830 
  
 Novo Nordisk Health Care AG 
 Andreasstrasse 15 
 CH – 8050 Zurich Oerlikon 
 Switzerland 
  
 Attention: Head of Hematology Business Unit 
 Fax: 011-41-43-222-4404 
  

	Re:	Research, Development and License Agreement Among Neose 

	  	Technologies, Inc. and Novo Nordisk A/S and Novo Nordisk 

	  	Health Care AG dated as of November 17, 2003 (the “Agreement”) 

	  	(relating to *****)
                                        
                                     

  
 Ladies and Gentlemen: 
  
 The purpose of this letter is to amend the Agreement in certain respects to reflect our
recent discussions. Capitalized terms used and not otherwise defined in this letter are used as defined in the Agreement. 
  
 1. Section 3.2.1 of the Agreement is hereby amended and restated in its entirety as follows: 
  
 ***** upon the ***** to occur of: (i) the first date on which there shall be
a candidate which has been shown to meet the *****, and Neose shall have delivered to Novo ***** for the production of such candidate; and (ii) the ***** anniversary of the Effective Date. 

 Novo Nordisk A/S 
 Novo Nordisk Health Care AS 
 December 18, 2003 
 Page 2 
  
 2. Section 5.1.1 of the Agreement is hereby amended and restated in its entirety as follows: 
  
 Exclusive License. As of the Effective Date, Neose hereby grants, and
agrees to grant, to Novo an exclusive (even as to Neose), royalty-bearing license in the Field of Use under the Neose Technology used or required to be used in the Field of Use during the Term, (i) to conduct research, sample, develop (including
clinical development), manufacture, make, use, market, promote, sell, offer for sale, have sold, distribute, import and export New Products in the Territory, and (ii) to use the Reagents in the Territory solely for the purpose of making New
Products. Such license does not permit Novo (x) to practice or use the Neose Technology outside the Field of Use or (y) to sublicense any of its rights without the prior written approval of Neose, except as provided in Section 5.1.2.

  
 3. Exhibit 1.24 to the Agreement is hereby amended and
restated as set forth in Attachment A to this letter agreement. 
  
 This letter
amends the Agreement only as herein set forth and in all other respects the Agreement is ratified and confirmed. Three originals of this letter amendment are enclosed in our Federal Express package, each of which has been executed on behalf of
Neose. Please indicate the agreement of Novo Nordisk A/S and Novo Nordisk Health Care AG with the terms of this letter by having this letter executed on behalf of each company in the space provided below, and return one fully executed copy to Neose
by fax (215-315-9100) and Federal Express or DHL courier (each to the attention of our General Counsel). 
  
 Sincerely yours, 
  
 NEOSE TECHNOLOGIES, INC. 
  

			
	 By:
	 	 /s/ George J. Vergis

	 Name:
	 	 George J. Vergis, Ph.D.

	 Title:
	 	Senior Vice President, Business and Commercial Development

 Novo Nordisk A/S 
 Novo Nordisk Health Care AS 
 December 18, 2003 
 Page 3 
  
 Accepted and agreed: 
  

									
	 NOVO NORDISK A/S
	 	 	 	 	 	 NOVO NORDISK HEALTH CARE AG

					
	 By:
	 	 /s/ Pierre Honore
	 	 	 	 By:
	 	 /s/ Klaus Ehrlich

	 	 	
	 	 	 	 	 	

	 Name:
	 	 Pierre Honore
	 	 	 	 Name:
	 	 Klaus Ehrlich

	 Title:
	 	 VP Scientific Licensing
	 	 	 	 Title:
	 	 SVP Europe

					
	 cc:
	 	 Novo Nordisk A/S
	 	 	 	 	 	 
	 	 	 Attention: General Counsel
	 	 	 	 	 	 
	 	 	 Fax: 011-45-4498-0670
	 	 	 	 	 	 

 ATTACHMENT A TO LETTER AMENDMENT DATED DECEMBER 18, 2003 
  

			
	 Confidential Information – Neose Technologies, Inc.
	  	EXHIBIT 1.24

  
 NEOSE PATENTS AS
OF THE DATE OF THIS AGREEMENT 
  

															
	 ******

	  	 	  	 	  	 	  	 	  	 	  	 	  	 
	 Country

	  	 Case Type

	  	 Status

	  	 Application Number

	  	 Filing Date

	  	 Patent Number

	  	 Issue Date

	  	 Expiration Date

	 ******
	  	PCT	  	Granted	  	******	  	******	  	******	  	******	  	******
	******	  	DIV	  	Pending	  	******	  	******	  	 	  	 	  	 
	******	  	PCT	  	Pending	  	******	  	******	  	 	  	 	  	 
	******	  	PCT	  	Published	  	******	  	******	  	 	  	 	  	 
	******	  	PCT	  	Pending	  	******	  	******	  	 	  	 	  	 
	******	  	PCT	  	Published	  	******	  	******	  	 	  	 	  	 
	******	  	PCT	  	Pending	  	******	  	******	  	 	  	 	  	 
	 ******
	  	PCT	  	Granted	  	******	  	******	  	******	  	******	  	******
	******	  	ORD	  	Pending	  	******	  	******	  	******	  	 	  	 
	******	  	CON	  	Pending	  	******	  	******	  	 	  	 	  	 
	******	  	CON	  	Published	  	******	  	******	  	 	  	 	  	 
	******	  	DIV	  	Published	  	******	  	******	  	 	  	 	  	 
	******	  	CON	  	Pending	  	******	  	******	  	 	  	 	  	 
	******	  	PRO	  	Expired	  	******	  	******	  	 	  	 	  	 
	 ******
	  	RCE	  	Granted	  	******	  	******	  	******	  	******	  	******
								
	 ******

	  	 	  	 	  	 	  	 	  	 	  	 	  	 
	 Country

	  	 Case Type

	  	 Status

	  	 Application Number

	  	 Filing Date

	  	 Patent Number

	  	 Issue Date

	  	 Expiration Date

	******	  	ORD	  	Published	  	******	  	******	  	******	  	 	  	 
	******	  	PRO	  	Expired	  	******	  	******	  	 	  	 	  	******
	******	  	PRO	  	Expired	  	******	  	******	  	 	  	 	  	******
	 ******
	  	PRO	  	Expired	  	******	  	******	  	 	  	 	  	******
	 ******
	  	PRO	  	Expired	  	******	  	******	  	 	  	 	  	******
								
	 ******

	  	 	  	 	  	 	  	 	  	 	  	 	  	 
	 Country

	  	 Case Type

	  	 Status

	  	 Application Number

	  	 Filing Date

	  	 Patent Number

	  	 Issue Date

	  	 Expiration Date

	******	  	CIP	  	Pending	  	******	  	******	  	 	  	 	  	 
								
	 ******

	  	 	  	 	  	 	  	 	  	 	  	 	  	 
	 Country

	  	 Case Type

	  	 Status

	  	 Application Number

	  	 Filing Date

	  	 Patent Number

	  	 Issue Date

	  	 Expiration Date

	******	  	CON	  	Pending	  	******	  	******	  	 	  	 	  	 

 ATTACHMENT A TO LETTER AMENDMENT DATED DECEMBER 18, 2003 
  

			
	 Confidential Information – Neose Technologies, Inc.
	  	EXHIBIT 1.24

  

															
	 ******

	  	 	  	 	  	 	  	 	  	 	  	 	  	 
	 Country

	  	 Case Type

	  	 Status

	  	 Application Number

	  	 Filing Date

	  	 Patent Number

	  	 Issue Date

	  	 Expiration Date

	******	  	CIP	  	Pending	  	******	  	******	  	 	  	 	  	 
								
	 ******

	  	 	  	 	  	 	  	 	  	 	  	 	  	 
	 Country

	  	 Case Type

	  	 Status

	  	 Application Number

	  	 Filing Date

	  	 Patent Number

	  	 Issue Date

	  	 Expiration Date

	******	  	CIP	  	Pending	  	******	  	******	  	 	  	 	  	 
								
	 ******

	  	 	  	 	  	 	  	 	  	 	  	 	  	 
	 Country

	  	 Case Type

	  	 Status

	  	 Application Number

	  	 Filing Date

	  	 Patent Number

	  	 Issue Date

	  	 Expiration Date

	******	  	CIP	  	Pending	  	******	  	******	  	 	  	 	  	 
								
	 ******

	  	 	  	 	  	 	  	 	  	 	  	 	  	 
	 Country

	  	 Case Type

	  	 Status

	  	 Application Number

	  	 Filing Date

	  	 Patent Number

	  	 Issue Date

	  	 Expiration Date

	******	  	PCT	  	Granted	  	******	  	******	  	******	  	******	  	******
	******	  	PCT	  	Published	  	******	  	******	  	 	  	 	  	 
	******	  	ORD	  	Published	  	******	  	******	  	******	  	 	  	 
	******	  	CIP	  	Granted	  	******	  	******	  	******	  	******	  	******

 ATTACHMENT A TO LETTER AMENDMENT DATED DECEMBER 18, 2003 
  

			
	 Confidential Information – Neose Technologies, Inc.
	  	EXHIBIT 1.24

  

															
	 ******

	  	 	  	 	  	 	  	 	  	 	  	 	  	 
	 Country

	  	 Case Type

	  	 Status

	  	 Application Number

	  	 Filing Date

	  	 Patent Number

	  	 Issue Date

	  	 Expiration Date

	 ******
	  	PCT	  	Granted	  	******	  	******	  	******	  	******	  	******
	 ******
	  	EPC	  	Granted	  	******	  	******	  	******	  	******	  	******
	 ******
	  	EPC	  	Granted	  	******	  	******	  	******	  	******	  	******
	 ******
	  	PCT	  	Granted	  	******	  	******	  	******	  	******	  	 
	 ******
	  	EPC	  	Granted	  	******	  	******	  	******	  	******	  	******
	 ******
	  	PCT	  	Granted	  	******	  	******	  	******	  	******	  	******
	 ******
	  	EPC	  	Granted	  	******	  	******	  	******	  	******	  	******
	 ******
	  	PCT	  	Granted	  	******	  	******	  	******	  	******	  	******
	 ******
	  	EPC	  	Granted	  	******	  	******	  	******	  	******	  	******
	 ******
	  	PCT	  	Granted	  	******	  	******	  	******	  	******	  	******
	 ******
	  	EPC	  	Granted	  	******	  	******	  	******	  	******	  	******
	 ******
	  	ORD	  	Published	  	******	  	******	  	******	  	 	  	 
	 ******
	  	EPC	  	Granted	  	******	  	******	  	******	  	******	  	******
	 ******
	  	EPC	  	Granted	  	******	  	******	  	******	  	******	  	******
	 ******
	  	EPC	  	Granted	  	******	  	******	  	******	  	******	  	******
	 ******
	  	EPC	  	Granted	  	******	  	******	  	******	  	******	  	******
	 ******
	  	ORD	  	Granted	  	******	  	******	  	******	  	******	  	******
	 ******
	  	CON	  	Granted	  	******	  	******	  	******	  	******	  	******
	 ******
	  	DIV	  	Granted	  	******	  	******	  	******	  	******	  	******

 ATTACHMENT A TO LETTER AMENDMENT DATED DECEMBER 18, 2003 
  

			
	 Confidential Information – Neose Technologies, Inc.
	  	EXHIBIT 1.24

  
 PROVISIONAL: The Parties
acknowledge that the following may be included by amendment. 
  

																	
	 ******

	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 
	 Country

	  	 Sub Case

	  	 Case Type

	  	 Status

	  	 Application Number

	  	 Filing Date

	  	 Patent Number

	  	 Issue Date

	  	 Expiration Date

	******	  	 	  	PCT	  	Published	  	******	  	******	  	 	  	 	  	 
	******	  	 	  	PCT	  	Published	  	 	  	******	  	 	  	 	  	 
	******	  	 	  	PCT	  	Published	  	******	  	******	  	 	  	 	  	 
	******	  	 	  	PCT	  	Published	  	 	  	******	  	 	  	 	  	 
	******	  	 	  	PCT	  	Published	  	 	  	******	  	 	  	 	  	 
	******	  	 	  	ORD	  	Published	  	******	  	******	  	******	  	 	  	 
	******	  	 	  	CIP	  	Allowed	  	******	  	******	  	 	  	 	  	 
	******	  	D1	  	DIV	  	Published	  	******	  	******	  	 	  	 	  	 
	******	  	D2	  	DIV	  	Published	  	******	  	******	  	 	  	 	  	 
	******	  	D3	  	DIV	  	Published	  	******	  	******	  	 	  	 	  	 
	******	  	D4	  	DIV	  	Published	  	******	  	******	  	 	  	 	  	 
	******	  	D5	  	DIV	  	Published	  	******	  	******Promissory Note

 EXHIBIT 10.43 
  
 PROMISSORY NOTE 
  
 12-18-03 

 (Date) 
  
 FOR VALUE RECEIVED, Neose
Technologies, Inc. a corporation located at the address stated below (“Maker”) promises, jointly and severally if more than one, to pay to the order of General Electric Capital Corporation or any subsequent holder hereof
(each, a “Payee”) at its office located at 401 Merritt 7 Suite 23, Norwalk, CT 06851-1177 or at such other place as Payee or the holder hereof may designate, the principal sum of One Million Two Hundred One Thousand Two
Hundred Ten and 41/100 Dollars ($1,201,210.41), with interest on the unpaid principal balance, from the date hereof through and including the dates of payment, at a fixed interest rate of Eight and Sixty-Six percent (8.66%) per annum, to be paid
in lawful money of the United States, in Forty -Eight (48) consecutive monthly installments of principal and interest as follows: 
  

				
	 Periodic
 Installment

	  	Amount

	 Thirty-Six (36)
	  	$	30,471.47
	 Eleven (11)
	  	$	26,940.77

  
 each (“Periodic
Installment”) and a final installment which shall be in the amount of the total outstanding principal and interest. The first Periodic Installment shall be due and payable on
                     and the following Periodic Installments and the final installment shall be due and payable on the same day of each
succeeding month (each, a “Payment Date”). Such installments have been calculated on the basis of a 360 day year of twelve 30-day months. Each payment may, at the option of the Payee, be calculated and applied on an assumption that such
payment would be made on its due date. 
  
 The acceptance by Payee of any payment
which is less than payment in full of all amounts due and owing at such time shall not constitute a waiver of Payee’s right to receive payment in full at such time or at any prior or subsequent time. 
  
 The Maker hereby expressly authorizes the Payee to insert the date value is actually given in
the blank space on the face hereof and on all related documents pertaining hereto. 
  
 This Note may be secured by a security agreement, chattel mortgage, pledge agreement or like instrument (each of which is hereinafter called a “Security Agreement”). 
  
 Time is of the essence hereof. If any installment or any other sum due under this Note or any
Security Agreement is not received within ten (10) days after its due date, the Maker agrees to pay, in addition to the amount of each such installment or other sum, a late payment charge of five percent (5%) of the amount of said installment or
other sum, but not exceeding any lawful maximum. If (i) Maker fails to make payment of any amount due hereunder within ten (10) days after the same becomes due and payable; or (ii) Maker is in default under, or fails to perform under any term or
condition contained in any Security Agreement, then the entire principal sum remaining unpaid, together with all accrued interest thereon and any other sum payable under this Note or any Security Agreement, at the election of Payee, shall
immediately become due and payable, with interest thereon at the lesser of eighteen percent (18%) per annum or the highest rate not prohibited by applicable law from the date of such accelerated maturity until paid (both before and after any
judgment). 
  
 Notwithstanding anything to the contrary contained herein or in the
Security Agreement, Maker may not prepay in full or in part any indebtedness hereunder without the express written consent of Payee in its sole discretion. 
  
 It is the intention of the parties hereto to comply with the applicable usury laws; accordingly, it is agreed that, notwithstanding any provision to the contrary in this
Note or any Security Agreement, in no event shall this Note or any Security Agreement require the payment or permit the collection of interest in excess of the maximum amount permitted by applicable law. If any such excess interest is contracted
for, charged or received under this Note or any Security Agreement, or if all of the principal balance shall be prepaid, so that under any of such circumstances the amount of interest contracted for, charged or received under this Note or any
Security Agreement on the principal balance shall exceed the maximum amount of interest permitted by applicable law, then in such event (a) the provisions of this paragraph shall govern and control, (b) neither Maker nor any other person or entity
now or hereafter liable for the payment hereof shall be obligated to pay the amount of such interest to the extent that it is in excess of the maximum amount of interest permitted by applicable law, (c) any such excess 

 which may have been collected shall be either applied as a credit against the then unpaid principal balance or refunded
to Maker, at the option of the Payee, and (d) the effective rate of interest shall be automatically reduced to the maximum lawful contract rate allowed under applicable law as now or hereafter construed by the courts having jurisdiction thereof. It
is further agreed that without limitation of the foregoing, all calculations of the rate of interest contracted for, charged or received under this Note or any Security Agreement which are made for the purpose of determining whether such rate
exceeds the maximum lawful contract rate, shall be made, to the extent permitted by applicable law, by amortizing, prorating, allocating and spreading in equal parts during the period of the full stated term of the indebtedness evidenced hereby, all
interest at any time contracted for, charged or received from Maker or otherwise by Payee in connection with such indebtedness; provided, however, that if any applicable state law is amended or the law of the United States of America preempts any
applicable state law, so that it becomes lawful for the Payee to receive a greater interest per annum rate than is presently allowed, the Maker agrees that, on the effective date of such amendment or preemption, as the case may be, the lawful
maximum hereunder shall be increased to the maximum interest per annum rate allowed by the amended state law or the law of the United States of America. 
  
 The Maker and all sureties, endorsers, guarantors or any others (each such person, other than the Maker, an “Obligor”) who may at any time become liable
for the payment hereof jointly and severally consent hereby to any and all extensions of time, renewals, waivers or modifications of, and all substitutions or releases of, security or of any party primarily or secondarily liable on this Note or any
Security Agreement or any term and provision of either, which may be made, granted or consented to by Payee, and agree that suit may be brought and maintained against any one or more of them, at the election of Payee without joinder of any other as
a party thereto, and that Payee shall not be required first to foreclose, proceed against, or exhaust any security hereof in order to enforce payment of this Note. The Maker and each Obligor hereby waives presentment, demand for payment, notice of
nonpayment, protest, notice of protest, notice of dishonor, and all other notices in connection herewith, as well as filing of suit (if permitted by law) and diligence in collecting this Note or enforcing any of the security hereof, and agrees to
pay (if permitted by law) all expenses incurred in collection, including Payee’s actual attorneys’ fees. Maker and each Obligor agrees that fees not in excess of twenty percent (20%) of the amount then due shall be deemed reasonable.

  
 Maker hereby irrevocably authorizes and empowers the Prothonotary or Clerk, or
any attorney for any Court of record to appear for Maker in such Courts, at any time, and confess a judgement against Maker, without process, in favor of any holder hereof, without the filing of a declaration of default, with release of errors,
without stay of execution, for such amount as may appear from the face hereof to be due hereunder (or, if such attorney so elects, for the amount which may be due hereon as evidenced by an affidavit signed by a representative of holder setting forth
the amount then due) together with charges, attorney’s fees and costs as herein provided, and Maker hereby waives and releases all benefits and relief from any and all appraisement, stay or exemption laws of any state, now in force or hereafter
to be passed. If a copy hereof, verified by an affidavit, shall have been filed in said proceeding, it shall not be necessary to file the original as a warrant of attorney. No single exercise of the foregoing warrant and power to confess judgement
shall be deemed to exhaust the power, whether or not such exercise shall be held by any Court to be invalid, voidable, or void, but the power shall continue undiminished and may be exercised from time to time as often as the holder hereof shall
elect, until all sums payable or that may become payable hereunder by Maker have been paid in full. 
  
 THE MAKER HEREBY UNCONDITIONALLY WAIVES ITS RIGHTS TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION BASED UPON OR ARISING OUT OF, DIRECTLY OR INDIRECTLY, THIS NOTE, ANY OF THE RELATED DOCUMENTS, ANY DEALINGS BETWEEN
MAKER AND PAYEE RELATING TO THE SUBJECT MATTER OF THIS TRANSACTION OR ANY RELATED TRANSACTIONS, AND/OR THE RELATIONSHIP THAT IS BEING ESTABLISHED BETWEEN MAKER AND PAYEE. THE SCOPE OF THIS WAIVER IS INTENDED TO BE ALL ENCOMPASSING OF ANY AND ALL
DISPUTES THAT MAY BE FILED IN ANY COURT (INCLUDING, WITHOUT LIMITATION, CONTRACT CLAIMS, TORT CLAIMS, BREACH OF DUTY CLAIMS, AND ALL OTHER COMMON LAW AND STATUTORY CLAIMS.) THIS WAIVER IS IRREVOCABLE MEANING THAT IT MAY NOT BE MODIFIED EITHER ORALLY
OR IN WRITING, AND THE WAIVER SHALL APPLY TO ANY SUBSEQUENT AMENDMENTS, RENEWALS, SUPPLEMENTS OR MODIFICATIONS TO THIS NOTE, ANY RELATED DOCUMENTS, OR TO ANY OTHER DOCUMENTS OR AGREEMENTS RELATING TO THIS TRANSACTION OR ANY RELATED TRANSACTION. IN
THE EVENT OF LITIGATION, THIS NOTE MAY BE FILED AS A WRITTEN CONSENT TO A TRIAL BY THE COURT. 
  
 This Note and any Security Agreement constitute the entire agreement of the Maker and Payee with respect to the subject matter hereof and supercedes all prior understandings, agreements and representations, express or
implied. 
  
 No variation or modification of this Note, or any waiver of any of
its provisions or conditions, shall be valid unless in writing and signed by an authorized representative of Maker and Payee. Any such waiver, consent, modification or change shall be effective only in the specific instance and for the specific
purpose given. 

 Any provision in this Note or any Security Agreement which is in conflict with any statute, law or applicable rule shall
be deemed omitted, modified or altered to conform thereto. 
  

							
	 	 	 	 	Neose Technologies, Inc.
				
	  

	 	 	 	 By:
	 	 /s/ A. Brian Davis

	 (Witness)
	 	 	 	 	 	 
				
	  

	 	 	 	 Name:
	 	 A. Brian Davis

	 (Print name)
	 	 	 	 	 	 
				
	  

	 	 	 	 Title:
	 	 Vice President, Finance

	 (Address)
  
	 	 	 	 	 	 
	 	 	 	 	 Federal Tax ID #: 13-3549286

			
	 	 	 	 	 Address: 102 Witmer Rd, Horsham, Montgomery County, PA 19044

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00061-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00061-of-00352.parquet"}]]